At a glance
- Originator Fujisawa
- Class Anti-ischaemics; Nonsteroidal anti-inflammatories
- Mechanism of Action Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 24 Jan 1995 Discontinued-II for Rheumatic disorders in USA (PO)
- 24 Jan 1995 Discontinued-III for Rheumatic disorders in Japan (PO)